Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1141-1150

  Chang, Pei Ying ^a,d   Peng, Shu Fen ^a   Lee, Chao Ying ^c   Lu, Chi Cheng ^b   Tsai, Shih Chang ^a   Shieh, Tzong Ming ^a   Wu, Tian Shung ^e   Tu, Ming Gene ^a,d   Chen, Michael Yuanchien ^a,d   Yang, Jai Sing ^b  

^a Department of Dentistry ^*  (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; CAL27 cisplatin resistant human oral cancer cells; Curcumin nanoparticles; Multiple drug resistance 1; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; AIF PROTEIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CALCEIN; CASPASE 3; CASPASE 9; CISPLATIN; CURCUMIN; CYTOCHROME C; DNA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY TEST; DNA FRAGMENTATION; DOWN REGULATION; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; FIBROBLAST; GENE EXPRESSION; GINGIVA; HUMAN; HUMAN CELL; KERATINOCYTE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CURCUMIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS; NANOPARTICLES; P-GLYCOPROTEIN; REACTIVE OXYGEN SPECIES;

EID: 84882409064     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2050     Document Type: Article

References (72)

1. Nagadia R, Pandit P, Coman WB, Cooper-White J and Punyadeera C: miRNAs in head and neck cancer revisited. Cell Oncol (Dordr) 36: 1-7, 2013.
2. Duvvuri U and Myers JN: Cancer of the head and neck is the sixth most common cancer worldwide. Curr Probl Surg 46: 114-117, 2009.
3. Chen YJ, Chang JT, Liao CT, et al: Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 99: 1507-1514, 2008.
4. Chang PM, Chen PM, Chu PY, et al: Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. Cancer Chemother Pharmacol 63: 9-17, 2008.
5. Chen MK, Su SC, Lin CW, Tsai CM, Yang SF and Weng CJ: Cathepsin B SNPs elevate the pathological development of oral cancer and raise the susceptibility to carcinogen-mediated oral cancer. Hum Genet 131: 1861-1868, 2012.
6. Lou JL, Guo L, Zhao JQ and Wang SY: Squamous cell carcinoma of cervical lymph nodes from an unknown primary site: a retrospective analysis of treatment strategies and prognosis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 48: 32-36, 2013 (In Chinese).
7. Bose P, Brockton NT and Dort JC: Head and neck cancer: from anatomy to biology. Int J Cancer: Feb 18, 2013 (Epub ahead of print).
8. Kubicek GJ, Kimler BF, Wang F, Reddy EK, Girod DA and Williamson SK: Chemotherapy in head and neck cancer: clinical predictors of tolerance and outcomes. Am J Clin Oncol 34: 380-384, 2011.
9. Rades D, Ulbricht T, Hakim SG and Schild SE: Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity. Strahlenther Onkol 188: 42-48, 2012.
10. Mandic R, Rodgarkia-Dara CJ, Krohn V, Wiegand S, Grenman R and Werner JA: Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor. Anticancer Res 29: 1181-1187, 2009.
11. Sunwoo JB: A cisplatin-resistant subpopulation of mesenchymal-like cells in head and neck squamous cell carcinoma. Cell Cycle 10: 2834-2835, 2011.
12. Vyas A, Dandawate P, Padhye S, Ahmad A and Sarkar F: Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des 19: 2047-2069, 2013.
13. Baliga MS, Joseph N, Venkataranganna MV, Saxena A, Ponemone V and Fayad R: Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Food Funct 3: 1109-1117, 2012.
14. Hanai H and Sugimoto K: Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 15: 2087-2094, 2009.
15. Li Y and Wang P: Neuroprotective effects of curcumin. Zhongguo Zhong Yao Za Zhi 34: 3173-3175, 2009 (In Chinese).
16. Shishodia S: Molecular mechanisms of curcumin action: gene expression. Biofactors 39: 37-55, 2013.
17. Noorafshan A and Ashkani-Esfahani S: A review of therapeutic effects of curcumin. Curr Pharm Des 19: 2032-2046, 2013.
18. Zhang X, Chen LX, Ouyang L, Cheng Y and Liu B: Plant natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents. Cell Prolif 45: 466-476, 2012.
19. Ye MX, Li Y, Yin H and Zhang J: Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci 13: 3959-3978, 2012.
20. Saha S, Adhikary A, Bhattacharyya P, Das T and Sa G: Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Res 32: 2567-2584, 2012.
21. Gupta SC, Kismali G and Aggarwal BB: Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 39: 2-13, 2013.
22. Gao W, Chan JY, Wei WI and Wong TS: Anti-cancer effects of curcumin on head and neck cancers. Anticancer Agents Med Chem 12: 1110-1116, 2012.
23. Yallapu MM, Jaggi M and Chauhan SC: Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today 17: 71-80, 2012.
24. Varinska L, Mirossay L, Mojzisova G and Mojzis J: Antiangogenic effect of selected phytochemicals. Pharmazie 65: 57-63, 2010.
25. Basnet P and Skalko-Basnet N: Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16: 4567-4598, 2011.
26. Haddad M, Sauvain M and Deharo E: Curcuma as a parasiticidal agent: a review. Planta Med 77: 672-678, 2011.
27. Ji JL, Huang XF and Zhu HL: Curcumin and its formulations: potential anti-cancer agents. Anticancer Agents Med Chem 12: 210-218, 2012.
28. Shehzad A, Wahid F and Lee YS: Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343: 489-499, 2010.
29. Epstein J, Sanderson IR and Macdonald TT: Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103: 1545-1557, 2010.
30. Yallapu MM, Ebeling MC, Khan S, et al: Novel curcumin loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther: May 23, 2013 (Epub ahead of print).
31. Pawar YB, Purohit H, Valicherla GR, et al: Novel lipid based oral formulation of curcumin: development and optimization by design of experiments approach. Int J Pharm 436: 617-623, 2012.
32. Gupta NK and Dixit VK: Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J Pharm Sci 100: 1987-1995, 2011.
33. Verderio P, Bonetti P, Colombo M, Pandolfi L and Prosperi D: Intracellular drug release from curcumin-loaded PLGA nanoparticles induces G2/M block in breast cancer cells. Biomacromolecules 14: 672-682, 2013.
34. Tsai YM, Chang-Liao WL, Chien CF, Lin LC and Tsai TH: Effects of polymer molecular weight on relative oral bioavailability of curcumin. Int J Nanomed 7: 2957-2966, 2012.
35. Doggui S, Sahni JK, Arseneault M, Dao L and Ramassamy C: Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimers Dis 30: 377-392, 2012.
36. Das M and Sahoo SK: Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 7: e32920, 2012.
37. Xie X, Tao Q, Zou Y, et al: PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem 59: 9280-9289, 2011.
38. Bansal SS, Goel M, Aqil F, Vadhanam MV and Gupta RC: Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) 4: 1158-1171, 2011.
39. Jain AK, Das M, Swarnakar NK and Jain S: Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst 28: 1-45, 2011.
40. Berginc K, Trontelj J, Basnet NS and Kristl A: Physiological barriers to the oral delivery of curcumin. Pharmazie 67: 518-524, 2012.
41. Shukla S, Zaher H, Hartz A, Bauer B, Ware JA and Ambudkar SV: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res 26: 480-487, 2009.
42. Yue GG, Cheng SW, Yu H, et al: The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells. J Med Food 15: 242-252, 2012.
43. Zhou S, Lim LY and Chowbay B: Herbal modulation of P-glycoprotein. Drug Metab Rev 36: 57-104, 2004.
44. Gosepath EM, Eckstein N, Hamacher A, et al: Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int J Cancer 123: 2013-2019, 2008.
45. Shih YH, Chang KW, Hsia SM, et al: In vitro antimicrobial and anticancer potential of hinokitiol against oral pathogens and oral cancer cell lines. Microbiol Res 168: 254-262, 2013.
46. Mathew A, Fukuda T, Nagaoka Y, et al: Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One 7: e32616, 2012.
47. Luz PP, Magalhaes LG, Pereira AC, Cunha WR, Rodrigues V and Andrade ESML: Curcumin-loaded into PLGA nanoparticles: preparation and in vitro schistosomicidal activity. Parasitol Res 110: 593-598, 2012.
48. Anand P, Nair HB, Sung B, et al: Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79: 330-338, 2010.
49. Koppolu B, Rahimi M, Nattama S, Wadajkar A and Nguyen KT: Development of multiple-layer polymeric particles for targeted and controlled drug delivery. Nanomedicine 6: 355-361, 2010.
50. Chang CM, Chang PY, Tu MG, et al: Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2. Oncol Rep 28: 1799-1807, 2012.
51. Tsai SC, Lu CC, Lee CY, et al: AKT serine/threonine protein kinase modulates bufalin-triggered intrinsic pathway of apoptosis in CAL 27 human oral cancer cells. Int J Oncol 41: 1683-1692, 2012.
52. Yallapu MM, Othman SF, Curtis ET, et al: Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomed 7: 1761-1779, 2012.
53. Tsai SC, Yang JS, Peng SF, et al: Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. Int J Oncol 41: 1431-1442, 2012.
54. Mozaffarieh M, Konieczka K, Hauenstein D, Schoetzau A and Flammer J: Half a pack of cigarettes a day more than doubles DNA breaks in circulating leukocytes. Tob Induc Dis 8: 14, 2010.
55. Kuo TC, Yang JS, Lin MW, et al: Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappaB in cell survival. J Pharmacol Exp Ther 330: 736-744, 2009.
56. Huang WW, Tsai SC, Peng SF, et al: Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human hepatic cancer cells. Int J Oncol 42: 2069-2077, 2013.
57. Lan YH, Chiang JH, Huang WW, et al: Activations of both extrinsic and intrinsic pathways in HCT 116 human colorectal cancer cells contribute to apoptosis through p53-mediated ATM/Fas signaling by Emilia sonchifolia extract, a folklore medicinal plant. Evid Based Complement Alternat Med 2012: 178178, 2012.
58. Lin C, Tsai SC, Tseng MT, et al: AKT serine/threonine protein kinase modulates baicalin-triggered autophagy in human bladder cancer T24 cells. Int J Oncol 42: 993-1000, 2013.
59. Taurin S, Nehoff H, Diong J, Larsen L, Rosengren RJ and Greish K: Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer. J Drug Target: May 16, 2013 (Epub ahead of print).
60. Yen FL, Wu TH, Tzeng CW, Lin LT and Lin CC: Curcumin nanoparticles improve the physicochemical properties of curcumin and effectively enhance its antioxidant and antihepatoma activities. J Agric Food Chem 58: 7376-7382, 2010.
61. Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818, 2007.
62. Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M and Chauhan SC: Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab 13: 120-128, 2012.
63. Yin HT, Zhang DG, Wu XL, Huang XE and Chen G: In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev 14: 409-412, 2013.
64. Misra R and Sahoo SK: Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 8: 852-866, 2011.
65. Pramanik D, Campbell NR, Das S, et al: A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 3: 640-650, 2012.
66. Ganta S, Devalapally H and Amiji M: Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci 99: 4630-4641, 2010.
67. Ganta S and Amiji M: Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6: 928-939, 2009.
68. Punfa W, Yodkeeree S, Pitchakarn P, Ampasavate C and Limtrakul P: Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin 33: 823-831, 2012.
69. Cort A, Ozdemir E, Timur M and Ozben T: Effects of curcumin on bleomycininduced oxidative stress in malignant testicular germ cell tumors. Mol Med Rep 6: 860-866, 2012.
70. Misra J, Chanda D, Kim DK, et al: Curcumin differentially regulates endoplasmic reticulum stress through transcriptional corepressor SMILE (small heterodimer partner-interacting leucine zipper protein)-mediated inhibition of CREBH (cAMP responsive element-binding protein H). J Biol Chem 286: 41972-41984, 2011.
71. Wahl H, Tan L, Griffith K, Choi M and Liu JR: Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 105: 104-112, 2007.
72. Dilnawaz F, Singh A and Sahoo SK: Transferrin-conjugated curcumin-loaded superparamagnetic iron oxide nanoparticles induce augmented cellular uptake and apoptosis in K562 cells. Acta Biomater 8: 704-719, 2012.